New data on prostate-cancer mortality after PSA screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The association between Selenium and Prostate Cancer: a Systematic Review and Meta-AnalysisAsian Pacific journal of cancer prevention : APJCP · 2018
   Pooled it
2. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.European urology · 2015
   Trial
3. A narrative review of sociodemographic risk and disparities in screening, diagnosis, treatment, and outcomes of the most common extrathoracic malignancies in the United States.Journal of thoracic disease · 2021
   Review
4. Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifiesOncotarget · 2019
   Article
5. Leveraging the Family Influence of Women in Prostate Cancer Efforts Targeting African American Men.Journal of racial and ethnic health disparities · 2018
   Article
6. Screening for Prostate Cancer:: Making sense of the US Preventative Services Task Force 2017 Draft Recommendation Statement.Delaware journal of public health · 2017
   Article
7. Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Genes & cancer · 2016
   Article
8. RNA biomarkers to facilitate the identification of aggressive prostate cancer.Molecular aspects of medicine · 2015
   Review
9. Expected population impacts of discontinued prostate-specific antigen screening.Cancer · 2014
   Article
10. Mouse models of prostate cancer: picking the best model for the question.Cancer metastasis reviews · 2014
    Review
11. Realizing the potential of plasma genotyping in an age of genotype-directed therapies.Journal of the National Cancer Institute · 2014
    Article
12. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.Current urology reports · 2013
    Article
13. Prostate cancer in 2012: Paradigm shifts in prostate cancer diagnosis and treatment.Nature reviews. Urology · 2013
    Article
14. It's NOT FAIR! Or is it? The promise and the tyranny of evidence-based performance assessment.Theoretical medicine and bioethics · 2012
    Article
15. PIRADS 2.0: what is new?Diagnostic and interventional radiology (Ankara, Turkey)
    Article
16. "Don't Want No Risk and Don't Want No Problems": Public Understandings of the Risks and Benefits of Non-Invasive Prenatal Testing in the United States.AJOB empirical bioethics
    Article
17. The biology of castration-resistant prostate cancer.Current problems in cancer
    Review

Corrections and comments

• Commented on by
  Prostate-cancer mortality after PSA screening.2012
• Comment on
  Prostate-cancer mortality at 11 years of follow-up.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as